Content Spotlight
Podcast: Sustainability equals efficiency, says eXmoor
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Indian CDMO Aragen has laid out aggressive expansion plans for capacity and multi-modality services following a $100 million investment from Singapore-based private equity (PE) fund Quadria Capital.
Deal-Making
Lonza joins the race for weight loss drugs with plans to produce an active pharmaceutical ingredient (API) for Iconovo’s intranasal biologic.
Contract development and manufacturing organization (CDMO) Samsung Biologics will provide manufacturing services for the client in what it calls its ‘largest ever contract’.
Facilities & Capacity
Company experts pointed to fast turnaround time as key to successfully launching a new autologous therapy in 2026.
The CEO of CRISPR Therapeutics gave attendees a peek into the future of off-the-shelf gene therapies at the JP Morgan conference in San Francisco, California.
Global Markets
Contract development and manufacturing organization (CDMO) Samsung Biologics will provide manufacturing services for the client in what it calls its ‘largest ever contract’.
Indian CDMO Aragen has laid out aggressive expansion plans for capacity and multi-modality services following a $100 million investment from Singapore-based private equity (PE) fund Quadria Capital.
Regulations
With BIOSECURE in limbo, the US government seeks other ways to protect American interests.
Indian CDMO Aragen has laid out aggressive expansion plans for capacity and multi-modality services following a $100 million investment from Singapore-based private equity (PE) fund Quadria Capital.
Content Spotlight
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Therapeutic Class
Scaling capacity takes center stage at JPM as Thermo Fisher’s CEO navigates evolving pharma landscape and policy shifts.
Company experts pointed to fast turnaround time as key to successfully launching a new autologous therapy in 2026.
Upstream & Downstream Processing
With BIOSECURE in limbo, the US government seeks other ways to protect American interests.
Company experts pointed to fast turnaround time as key to successfully launching a new autologous therapy in 2026.